BMS-986278

BMS-986278
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (1S,3S)-3-[2-Methyl-6-[1-methyl-5-[[methyl(propyl)carbamoyl]oxymethyl]triazol-4-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid;
CAS Number	2170126-74-4;
PubChem CID	132232205;
ChemSpider	115009679;
UNII	4UN9AOU6G8;
ChEMBL	ChEMBL5087506;
Chemical and physical data
Formula	C22H31N5O5
Molar mass	445.520 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCN(C)C(=O)OCC1=C(N=NN1C)C2=NC(=C(C=C2)O[C@H]3CCC[C@@H](C3)C(=O)O)C;
	InChI InChI=1S/C22H31N5O5/c1-5-11-26(3)22(30)31-13-18-20(24-25-27(18)4)17-9-10-19(14(2)23-17)32-16-8-6-7-15(12-16)21(28)29/h9-10,15-16H,5-8,11-13H2,1-4H3,(H,28,29)/t15-,16-/m0/s1; Key:UEUNDURNLYLSNB-HOTGVXAUSA-N;

BMS-986278 is an experimental small-molecule drug and lysophosphatidic acid receptor 1 (LPA1) antagonist developed by Bristol Myers Squibb for idiopathic pulmonary fibrosis.^[1]^[2]^[3]

References

^ Murphy, Brian; Sum, Chi-Shing; Wang, Tao; Heiry, Rebekah; Kalinowski, Stephen; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony; Milinda, Ziegler; Burns, Lisa; Zinker, Bradley; Boehm, Stephanie; Taylor, Joseph; Sapuppo, Julia; Kathy, Mosure; Mary-Ellen, Cvijic; Kaltenbach, Robert; Dhanusu, Suresh; Tao, Shiwei; Zhang, Hao; Kennedy, Larry; Shi, Jun; Li, Jun; Walker, Steve; Shi, Yan; Wang, Ying; Reddigunta, Ramesh; Jeffrey, Roble; Ellsworth, Bruce; Gordon, David; Soars, Matt; Gill, Michael; Cheng, Peter (28 September 2019). "LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation". Idiopathic interstitial pneumonias. pp. PA5383. doi:10.1183/13993003.congress-2019.PA5383. S2CID 213747321.
^ Cheng, Peter T. W.; Kaltenbach, Robert F.; Zhang, Hao; Shi, Jun; Tao, Shiwei; Li, Jun; Kennedy, Lawrence J.; Walker, Steven J.; Shi, Yan; Wang, Ying; Dhanusu, Suresh; Reddigunta, Ramesh; Kumaravel, Selvakumar; Jusuf, Sutjano; Smith, Daniel; Krishnananthan, Subramaniam; Li, Jianqing; Wang, Tao; Heiry, Rebekah; Sum, Chi Shing; Kalinowski, Stephen S.; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony V.; Ziegler, Milinda; Burns, Lisa; Zinker, Bradley A.; Boehm, Stephanie; Taylor, Joseph; Sapuppo, Julia; Mosure, Kathy; Everlof, Gerry; Guarino, Victor; Zhang, Lisa; Yang, Yanou; Ruan, Qian; Xu, Carrie; Apedo, Atsu; Traeger, Sarah C.; Cvijic, Mary Ellen; Lentz, Kimberley A.; Tirucherai, Giridhar; Sivaraman, Lakshmi; Robl, Jeffrey; Ellsworth, Bruce A.; Rosen, Glenn; Gordon, David A.; Soars, Matthew G.; Gill, Michael; Murphy, Brian J. (11 November 2021). "Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases". Journal of Medicinal Chemistry. 64 (21): 15549–15581. doi:10.1021/acs.jmedchem.1c01256. PMID 34709814. S2CID 240153845.
^ Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi; Minnich, Anne; Zhan, Xiaojiang; Tirucherai, Giridhar S; Elpers, Brandon; Xiao, Hong; Watanabe, Hideaki; Smith, R Adam; Charles, Edgar D; Fischer, Aryeh (December 2021). "Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)". BMJ Open Respiratory Research. 8 (1): e001026. doi:10.1136/bmjresp-2021-001026. PMC 8718498. PMID 34969771.

[1] Murphy, Brian; Sum, Chi-Shing; Wang, Tao; Heiry, Rebekah; Kalinowski, Stephen; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony; Milinda, Ziegler; Burns, Lisa; Zinker, Bradley; Boehm, Stephanie; Taylor, Joseph; Sapuppo, Julia; Kathy, Mosure; Mary-Ellen, Cvijic; Kaltenbach, Robert; Dhanusu, Suresh; Tao, Shiwei; Zhang, Hao; Kennedy, Larry; Shi, Jun; Li, Jun; Walker, Steve; Shi, Yan; Wang, Ying; Reddigunta, Ramesh; Jeffrey, Roble; Ellsworth, Bruce; Gordon, David; Soars, Matt; Gill, Michael; Cheng, Peter (28 September 2019). "LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation". Idiopathic interstitial pneumonias. pp. PA5383. doi:10.1183/13993003.congress-2019.PA5383. S2CID 213747321.

[2] Cheng, Peter T. W.; Kaltenbach, Robert F.; Zhang, Hao; Shi, Jun; Tao, Shiwei; Li, Jun; Kennedy, Lawrence J.; Walker, Steven J.; Shi, Yan; Wang, Ying; Dhanusu, Suresh; Reddigunta, Ramesh; Kumaravel, Selvakumar; Jusuf, Sutjano; Smith, Daniel; Krishnananthan, Subramaniam; Li, Jianqing; Wang, Tao; Heiry, Rebekah; Sum, Chi Shing; Kalinowski, Stephen S.; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony V.; Ziegler, Milinda; Burns, Lisa; Zinker, Bradley A.; Boehm, Stephanie; Taylor, Joseph; Sapuppo, Julia; Mosure, Kathy; Everlof, Gerry; Guarino, Victor; Zhang, Lisa; Yang, Yanou; Ruan, Qian; Xu, Carrie; Apedo, Atsu; Traeger, Sarah C.; Cvijic, Mary Ellen; Lentz, Kimberley A.; Tirucherai, Giridhar; Sivaraman, Lakshmi; Robl, Jeffrey; Ellsworth, Bruce A.; Rosen, Glenn; Gordon, David A.; Soars, Matthew G.; Gill, Michael; Murphy, Brian J. (11 November 2021). "Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases". Journal of Medicinal Chemistry. 64 (21): 15549–15581. doi:10.1021/acs.jmedchem.1c01256. PMID 34709814. S2CID 240153845.

[3] Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi; Minnich, Anne; Zhan, Xiaojiang; Tirucherai, Giridhar S; Elpers, Brandon; Xiao, Hong; Watanabe, Hideaki; Smith, R Adam; Charles, Edgar D; Fischer, Aryeh (December 2021). "Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)". BMJ Open Respiratory Research. 8 (1): e001026. doi:10.1136/bmjresp-2021-001026. PMC 8718498. PMID 34969771.

[1]

[2]

[3]